GlaxoSmithKline pays $150 million in Medicare fraud case
September 20, 2005
GlaxoSmithKline has agreed to pay more than $150 million to settle fraud allegations over the pricing of two anti-nausea drugs for federal health programs, the Justice Department said Tuesday.
James Moorman, president of the advocacy group Taxpayers Against Fraud, said whistle-blower claims have so far resulted in $2.4 billion in settlements with drug companies.
